Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial

被引：0

作者：

Wei, Lai ^{[1
]}

Xie, Qing ^{[2
]}

Huang, Yan ^{[3
]}

Wu, Shanming ^{[4
]}

Xu, Min ^{[5
]}

Tang, Hong ^{[6
]}

Cheng, Jun ^{[7
]}

Gao, Yanhang ^{[8
]}

Mou, Zhuangbo ^{[9
]}

Dou, Xiaoguang ^{[10
]}

Nan, Yuemin ^{[11
]}

Ning, Qin ^{[12
]}

Mao, Yimin ^{[13
]}

Stamm, Luisa ^{[14
]}

Lu, Sophia ^{[14
]}

Dvory-Sobol, Hadas ^{[14
]}

Mo, Hongmei ^{[14
]}

Brainard, Diana ^{[14
]}

Yang, Yongfeng ^{[15
]}

Wang, Guiqiang ^{[16
]}

Hu, Peng ^{[17
]}

Zhang, Lunli ^{[18
]}

Gao, Zhiliang ^{[19
]}

Lin, Feng ^{[20
]}

Shang, Jia ^{[21
]}

Gong, Guozhong ^{[22
]}

Li, Jun ^{[23
]}

Su, Minghua ^{[24
]}

Duan, Zhongping ^{[25
]}

Hou, Jinlin ^{[26
]}

Jia, Jidong ^{[27
]}

机构：

[1] Peking Univ, Peoples Hosp, Inst Hepatol, Beijing, Peoples R China

[2] Ruijin Hosp, Shanghai, Peoples R China

[3] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China

[4] Shanghai Publ Hlth Ctr, Shanghai, Peoples R China

[5] Guangzhou Eighth Municipal Peoples Hosp, Guangzhou, Guangdong, Peoples R China

[6] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China

[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[9] Jinan Infect Dis Hosp, Jinan, Shandong, Peoples R China

[10] China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China

[11] Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China

[12] Tongji Hosp, Shanghai, Peoples R China

[13] Shanghai Renji Hosp, Shanghai, Peoples R China

[14] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[15] Second Hosp Nanjing, Nanjing, Jiangsu, Peoples R China

[16] Peking Univ, Hosp 1, Beijing, Peoples R China

[17] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China

[18] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[19] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China

[20] Hainan Gen Hosp, Haikou, Hainan, Peoples R China

[21] Henan Prov Peoples Hosp, Zhengzhou, Henan, Peoples R China

[22] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China

[23] Nanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China

[24] Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China

[25] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[26] Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[27] Beijing Friendship Hosp, Beijing, Peoples R China

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

637

引用

页码：379A / 379A

页数：1

共 50 条

[31] Decreased efficacy of sofosbuvir/velpatasvir in HIV patients coinfected with HCV genotype 3b
Zhou, Jing
Wang, Fa-Da
Li, Lan-Qing
Li, Jing-Yu
Chen, En-Qiang
FUTURE VIROLOGY, 2024, 19 (01) : 33 - 45
[32] A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study
Foster, Graham R.
Thompson, Alex J.
Ruane, Peter J.
Borgia, Sergio M.
Dore, Gregory
Workowski, Kimberly
Hyland, Robert H.
Wang, Jing
Svarovskaia, Evguenia S.
Stamm, Luisa M.
Brainard, Diana M.
Subramanian, Mani
McHutchison, John G.
Berg, Thomas
Agarwal, Kosh
Conway, Brian
Feld, Jordan J.
Willems, Bernard E.
Roberts, Stuart K.
HEPATOLOGY, 2016, 64 : 135A - 136A
[33] Integrated Resistance Analyses of HCV-infected Patients treated with Sofosbuvir, Velpatasvir and Voxilaprevir for 8 and 12 weeks from Phase 2 Studies
Reau, Nancy
Nguyen, Mindie H.
Kowdley, Kris V.
Gane, Edward J.
Dvory-Sobol, Hadas
Svarovskaia, Evguenia S.
Yang, Jenny C.
Stamm, Luisa M.
Brainard, Diana M.
Miller, Michael D.
Mo, Hongmei
Lawitz, Eric
Kwo, Paul Y.
Curry, Michael P.
Jacobson, Ira M.
HEPATOLOGY, 2016, 64 : 415A - 416A
[34] Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study
Sterling, Richard
Zeuzem, Stefan
Welzel, Tania
Manns, Michael P.
Reddy, Rajender
Terrault, Norah
Ben Ari, Ziv
Vodkin, Irine
Toor, Arifa
Vainorius, Monika
Akushevich, Lucy
Fried, Michael W.
Nelson, David R.
Sulkowski, Mark
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E241 - E242
[35] SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF HCV GENOTYPE 1-6: RESULTS OF THE HCV-TARGET STUDY
Sterling, Richard K.
Zeuzem, Stefan
Welzel, Tania M.
Manns, Michael
Reddy, K. Rajender
Terrault, Norah
Ben-Ari, Ziv
Vodkin, Irine
Toor, Arifa
Vainorius, Monika
Akushevich, Lucy
Fried, Michael W.
Nelson, David R.
Sulkowski, Mark S.
GASTROENTEROLOGY, 2019, 156 (06) : S1220 - S1220
[36] Safety and Efficacy of Treatment with Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients with Severe Renal Impairment
Martin, Paul
Gane, Edward J.
Ortiz-Lasanta, Grisell
Liu, Lin
Sajwani, Karim
Kirby, Brian
Denning, Jill M.
Stamm, Luisa M.
Brainard, Diana M.
McHutchison, John G.
Lawitz, Eric
Gordon, Stuart C.
Robson, Richard A.
HEPATOLOGY, 2015, 62 : 765A - 766A
[37] No Resistance Detected in four Phase 3 Clinical Studies in HCV Genotype 1-6 of Sofosbuvir plus Ribavirin with or without Peginterferon
Svarovskaia, Evguenia S.
Dvory, Hadas S.
Hebner, Christy
Doehle, Brian
Gontcharova, Viktoria
Martin, Ross
Gane, Edward J.
Jacobson, Ira M.
Nelson, David R.
Lawitz, Eric
Bekele, B. Nebiyou
Brainard, Diana M.
Symonds, William T.
McHutchison, John G.
Miller, Michael D.
Mo, Hongmei
HEPATOLOGY, 2013, 58 : 1091A - 1092A
[38] EFFICACY AND SAFETY OF SOFOSBUVIR/ VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN HCV- INFECTED CHINESE PATIENTS: A PROSPECTIVE COHORT STUDY
Wang, Jiayi
Du, Lingyao
Zhou, Chen
Zeng, Yilan
Chen, Enqiang
Zhang, Dong-Mei
Cheng, Xing
Song, Xiaona
Han, Ning
Liu, Miao
Chen, Han
Tang, Hong
HEPATOLOGY, 2023, 78 : S718 - S719
[39] The efficacy of sofosbuvir/velpatasvir/ribavirin in cirrhotic, genotype 3a HCV patients, previously failures to sofosbuvir/daclatasvir/ribavirin combination
Dimitroulopoulos, D.
Karatapanis, S.
Kypreos, D.
Malahias, A.
Tsamakidis, K.
Xinopoulos, D.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 71 - 71
[40] Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: An Integrated Analysis of Phase 2 and Phase 3 Clinical Trials
Roberts, Stuart Keith
Buti, Maria
Foster, Graham R.
Luis Calleja, Jose
Sood, Ajit
Isakov, Vasily A.
Ola, R.
Weiland, Hj
Stamm, Luisa
Ni, Liyun
Svarovskaia, Evguenia
Brainard, Diana
Wyles, David L.
Antonio Pineda, Juan
Thompson, Alexander
Esteban, Rafael
Mangia, Alessandra
HEPATOLOGY, 2018, 68 : 373A - 374A

← 1 2 3 4 5 →